Cornerstone acquires hyponatremia drug in Cardiokine buy
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics revealed on 4 January that it ended 2011 by acquiring specialty pharma Cardiokine, which brought the Cary, North Carolina drug maker a new experimental hyponatremia medicine, lixivaptan, whose new drug application (NDA) was submitted to the US FDA one day before the merger agreement was completed on 30 December.